Post Profile






Talimogene laherparepvec in melanoma: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) The data from the only study cited by the drug manufacturer in its dossier were unsuitable for the assessment.
read more

share
See more about: Health Care

Related Posts


Ipilimumab in advanced melanoma: Added benefit for non-pretreated patients not proven

Academics / General Science : Science Codex

The German Institute for Quality and Efficiency in Health Care (IQWiG) already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previ...

Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven

Academics / General Science : Science Codex

The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether the drug combination netupitant/palonosetron (trade name: Akynzeo) offers an added benefit over the appropriate comparat...

Nivolumab in melanoma: Data subsequently submitted improve assessment result

Academics / General Science : Science Codex

Nivolumab (trade name: Opdivo) has been approved since June 2015 for adults with advanced melanoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) had examined its added benefit in a dossier assessment comple...

Selexipag in pulmonary arterial hypertension: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.

Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven

Academics / General Science : Science Codex

In early 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ipilimumab in non-pretreated patients with advanced melanoma. The drug manufacturer claimed a noticeable increase in...

Comments


Copyright © 2016 Regator, LLC